Skip to main content
YUNGJIN PHARM. CO., LTD logo

YUNGJIN PHARM. CO., LTD — Investor Relations & Filings

Ticker · 003520 ISIN · KR7003520004 KO Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2025-03-28 Declaration of Voting R…
Country KR South Korea
Listing KO 003520

About YUNGJIN PHARM. CO., LTD

https://eng.yungjin.co.kr/

Yungjin Pharm. Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products for domestic and international markets. The company's portfolio includes a range of prescription drugs, with a focus on areas such as cephalosporin antibiotics and antipsychotic medications. Yungjin Pharm is actively involved in advancing its R&D pipeline, which includes collaborative research for treatments of rare conditions like mitochondrial diseases. Leveraging extensive drug production expertise and R&D capabilities, the company operates as a key affiliate within the KT&G Group's bio/pharmaceutical business.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (Annual General Meeting). It details the approval of financial statements, dividend decisions, and the election of directors and auditors. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the official outcome of the shareholder votes held on 2025-03-28.
2025-03-28 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or dismissal of outside directors (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This type of disclosure specifically concerns changes in the composition of the board of directors, which falls under the 'Board/Management Information' category.
2025-03-28 Korean
사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Yungjin Pharm Co., Ltd. for the fiscal year 2024 (ending Dec 31, 2024). It contains comprehensive financial statements, management discussion and analysis, governance information, and audit details. This is the standard Korean regulatory filing equivalent to a 10-K, which is classified as an Annual Report. FY 2024
2025-03-20 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Yungjin Pharm Co., Ltd. It details the agenda for the 63rd Annual General Meeting, including items such as the approval of financial statements, election of directors, and remuneration limits. It also contains management information, governance details, and financial summaries intended for shareholder review prior to the meeting. This aligns with the definition of AGM-R (Annual General Meeting materials).
2025-03-12 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy/Voting Rights) for Youngjin Pharm Co., Ltd. It contains information regarding the upcoming Annual General Meeting (AGM), including the purpose of the meeting, voting procedures (electronic/written), and details on the agenda items such as the approval of financial statements. This document is a standard proxy solicitation material provided to shareholders to request their votes for the AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-12 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal notification filed with the Korea Exchange (KRX) regarding the company's decision to hold its Annual General Meeting (AGM) on a 'concentrated date' (a date when many other companies also hold their AGMs). It explains the scheduling conflict and provides the date of the meeting. Since this is a regulatory disclosure regarding the scheduling of a shareholder meeting rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2025-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.